Site 0323 - Compass Oncology — Vancouver, Washington

Site 0323 - Compass Oncology is a clinical research site located in Vancouver, Washington, United States 98684.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Site 0323 - Compass Oncology has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Sponsors: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Vancouver

Browse all research sites in Washington · View every site in Vancouver

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site 0323 - Compass Oncology?

Site 0323 - Compass Oncology has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site 0323 - Compass Oncology conducted?

Site 0323 - Compass Oncology has 1 clinical trials on record, with 1 currently active. Their work covers High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Is Site 0323 - Compass Oncology accredited by Crixeo Clinical Trials?

Site 0323 - Compass Oncology has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site 0323 - Compass Oncology?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.